Literature DB >> 29724658

Human hepatocyte transplantation corrects the inherited metabolic liver disorder arginase deficiency in mice.

Stephanie A K Angarita1, Brian Truong2, Suhail Khoja1, Matthew Nitzahn3, Abha K Rajbhandari4, Irina Zhuravka4, Sergio Duarte1, Michael G Lin1, Alex K Lam1, Stephen D Cederbaum5, Gerald S Lipshutz6.   

Abstract

The transplantation, engraftment, and expansion of primary hepatocytes have the potential to be an effective therapy for metabolic disorders of the liver including those of nitrogen metabolism. To date, such methods for the treatment of urea cycle disorders in murine models has only been minimally explored. Arginase deficiency, an inherited disorder of nitrogen metabolism that presents in the first two years of life, has the potential to be treated by such methods. To explore the potential of this approach, we mated the conditional arginase deficient mouse with a mouse model deficient in fumarylacetoacetate hydrolase (FAH) and with Rag2 and IL2-Rγ mutations to give a selective advantage to transplanted (normal) human hepatocytes. On day -1, a uroplasminogen-expressing adenoviral vector was administered intravenously followed the next day with the transplantation of 1 × 106 human hepatocytes (or vehicle alone) by intrasplenic injection. As the initial number of administered hepatocytes would be too low to prevent hepatotoxicity-induced mortality, NTBC cycling was performed to allow for hepatocyte expansion and repopulation. While all control mice died, all except one human hepatocyte transplanted mice survived. Four months after hepatocyte transplantation, 2 × 1011 genome copies of AAV-TBG-Cre recombinase was administered IV to disrupt endogenous hepatic arginase expression. While all control mice died within the first month, human hepatocyte transplanted mice did well. Ammonia and amino acids, analyzed in both groups before and after disruption of endogenous arginase expression, while well-controlled in the transplanted group, were markedly abnormal in the controls. Ammonium challenging further demonstrated the durability and functionality of the human repopulated liver. In conclusion, these studies demonstrate that human hepatocyte repopulation in the murine liver can result in effective treatment of arginase deficiency.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Ammonia; Arginase deficiency; Cellular transplant; Hyperargininemia; Treatment; Urea cycle disorder

Mesh:

Substances:

Year:  2018        PMID: 29724658      PMCID: PMC5976549          DOI: 10.1016/j.ymgme.2018.04.005

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  22 in total

Review 1.  Chimeric mice with humanized liver: tools for the study of drug metabolism, excretion, and toxicity.

Authors:  Stephen C Strom; Julio Davila; Markus Grompe
Journal:  Methods Mol Biol       Date:  2010

2.  Behavioral and functional analysis of mouse phenotype: SHIRPA, a proposed protocol for comprehensive phenotype assessment.

Authors:  D C Rogers; E M Fisher; S D Brown; J Peters; A J Hunter; J E Martin
Journal:  Mamm Genome       Date:  1997-10       Impact factor: 2.957

Review 3.  Argininemia: a treatable genetic cause of progressive spastic diplegia simulating cerebral palsy: case reports and literature review.

Authors:  A N Prasad; J C Breen; M G Ampola; N P Rosman
Journal:  J Child Neurol       Date:  1997-08       Impact factor: 1.987

4.  RH10 provides superior transgene expression in mice when compared with natural AAV serotypes for neonatal gene therapy.

Authors:  Chuhong Hu; Ronald W Busuttil; Gerald S Lipshutz
Journal:  J Gene Med       Date:  2010-09       Impact factor: 4.565

Review 5.  Mice with human livers.

Authors:  Markus Grompe; Stephen Strom
Journal:  Gastroenterology       Date:  2013-09-13       Impact factor: 22.682

Review 6.  The human arginases and arginase deficiency.

Authors:  R Iyer; C P Jenkinson; J G Vockley; R M Kern; W W Grody; S Cederbaum
Journal:  J Inherit Metab Dis       Date:  1998       Impact factor: 4.982

7.  Toll-like receptor-induced arginase 1 in macrophages thwarts effective immunity against intracellular pathogens.

Authors:  Karim C El Kasmi; Joseph E Qualls; John T Pesce; Amber M Smith; Robert W Thompson; Marcela Henao-Tamayo; Randall J Basaraba; Till König; Ulrike Schleicher; Mi-Sun Koo; Gilla Kaplan; Katherine A Fitzgerald; Elaine I Tuomanen; Ian M Orme; Thirumala-Devi Kanneganti; Christian Bogdan; Thomas A Wynn; Peter J Murray
Journal:  Nat Immunol       Date:  2008-11-02       Impact factor: 25.606

8.  Short-term correction of arginase deficiency in a neonatal murine model with a helper-dependent adenoviral vector.

Authors:  Chia-Ling Gau; Robin A Rosenblatt; Vincenzo Cerullo; Fides D Lay; Adrienne C Dow; Justin Livesay; Nicola Brunetti-Pierri; Brendan Lee; Stephen D Cederbaum; Wayne W Grody; Gerald S Lipshutz
Journal:  Mol Ther       Date:  2009-04-14       Impact factor: 11.454

9.  Myocyte-mediated arginase expression controls hyperargininemia but not hyperammonemia in arginase-deficient mice.

Authors:  Chuhong Hu; Jennifer Kasten; Hana Park; Ragini Bhargava; Denise S Tai; Wayne W Grody; Quynh G Nguyen; Stephen D Hauschka; Stephen D Cederbaum; Gerald S Lipshutz
Journal:  Mol Ther       Date:  2014-06-03       Impact factor: 11.454

10.  Liver-specific knockout of arginase-1 leads to a profound phenotype similar to inducible whole body arginase-1 deficiency.

Authors:  Laurel L Ballantyne; Yuan Yan Sin; Osama Y Al-Dirbashi; Xinzhi Li; David J Hurlbut; Colin D Funk
Journal:  Mol Genet Metab Rep       Date:  2016-10-12
View more
  4 in total

Review 1.  Liver-humanized mice: A translational strategy to study metabolic disorders.

Authors:  Yonghong Luo; Haocheng Lu; Daoquan Peng; Xiangbo Ruan; Yuqing Eugene Chen; Yanhong Guo
Journal:  J Cell Physiol       Date:  2021-10-18       Impact factor: 6.513

2.  Lipid nanoparticle-targeted mRNA therapy as a treatment for the inherited metabolic liver disorder arginase deficiency.

Authors:  Brian Truong; Gabriella Allegri; Xiao-Bo Liu; Kristine E Burke; Xuling Zhu; Stephen D Cederbaum; Johannes Häberle; Paolo G V Martini; Gerald S Lipshutz
Journal:  Proc Natl Acad Sci U S A       Date:  2019-09-09       Impact factor: 11.205

3.  High Dose Versus Low Dose Syngeneic Hepatocyte Transplantation in Pex1-G844D NMRI Mouse Model is Safe but Does Not Achieve Long Term Engraftment.

Authors:  Tanguy Demaret; Jonathan Evraerts; Joachim Ravau; Martin Roumain; Giulio G Muccioli; Mustapha Najimi; Etienne M Sokal
Journal:  Cells       Date:  2020-12-30       Impact factor: 6.600

4.  CRISPR-Mediated Genomic Addition to CPS1 Deficient iPSCs is Insufficient to Restore Nitrogen Homeostasis.

Authors:  Matthew Nitzahn; Brian Truong; Suhail Khoja; Agustin Vega-Crespo; Colleen Le; Adam Eliav; Georgios Makris; April D Pyle; Johannes Häberle; Gerald S Lipshutz
Journal:  Yale J Biol Med       Date:  2021-12-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.